1型糖尿病肾移植受者中肾后胰岛移植与单纯肾移植的比较(KAIAK):法国一项基于人群的目标试验模拟
这项在法国开展的回顾性队列研究基于全国CRISTAL登记库,模拟目标试验,比较1型糖尿病肾移植受者接受肾后胰岛移植(IAK)与单纯肾移植的疗效。40例IAK患者与80例单纯肾移植患者按1:2时间依赖倾向评分匹配。IAK组患者-移植物生存显著优于单纯肾移植组(HR 0.44,95%CI 0.23-0.88;p=0.022),主要归因于死亡风险降低(HR 0.41,0.13-0.91;p=0.042)。
要点
- IAK移植与更好的患者-移植物生存相关(HR 0.44,95%CI 0.23-0.88;p=0.022)。
- 生存获益主要来自死亡风险降低(HR 0.41,95%CI 0.13-0.91;p=0.042)。
- IAK与删失死亡后的移植物生存无显著关联(HR 0.73,95%CI 0.30-1.89;p=0.36)。
核心结论
- 在1型糖尿病肾移植受者中,肾后胰岛移植与单纯肾移植相比,患者-移植物生存显著更好,主要由于对死亡风险的保护效应。
研究设计与样本
- 回顾性队列研究,基于法国CRISTAL全国登记库,纳入2000年1月1日至2017年12月31日期间接受肾移植的全部1型糖尿病患者,采用1:2时间依赖倾向评分匹配比较肾后胰岛移植(IAK)与单纯肾移植。
主要发现
- 2000年1月1日至2017年12月31日期间,2391例1型糖尿病患者被识别为接受肾移植,其中47例同时接受了胰岛移植。
- 2002例患者不符合胰岛移植条件,62例因数据缺失被排除;来自15个中心的327例合格受者纳入目标试验模拟的研究数据集。
- 40例接受IAK移植的患者成功匹配80例单纯肾移植患者。
- IAK移植组40例中13例(33%)恢复透析或死亡,单纯肾移植组80例中36例(45%)恢复透析或死亡。
- IAK与单纯肾移植相比,患者-移植物生存获益显著(HR 0.44,95%CI 0.23-0.88;p=0.022),主要归因于死亡风险的保护效应(HR 0.41,95%CI 0.13-0.91;p=0.042)。
临床怎么用
- 作者认为,这些结果可能为倡导在接受肾移植的1型糖尿病患者中更广泛地使用胰岛移植提供有力依据,因为全球仅有少数国家报销胰岛移植。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Islet transplantation has been associated with better metabolic control and quality of life than insulin treatment alone, but direct evidence of its effect on hard clinical endpoints is scarce. We aimed to assess the effect of islet transplantation on patient-graft survival in kidney transplant recipients with type 1 diabetes. METHODS: In this retrospective cohort study, we enrolled all patients with type 1 diabetes who received a kidney graft in France during the study period, identified from the CRISTAL nationwide registry. Non-inclusion criteria included recipients from transplant centres that never proposed islet transplantation during the study period, recipients with a functional pancreas throughout the follow-up duration, recipients with more than two kidney transplants, HLA-sensitised recipients, recipients with less than 1 year of follow-up after kidney transplantation, misclassified recipients with type 2 diabetes, recipients aged over 65 years, recipients of kidney grafts from Donation after Circulatory Death donors, recipient with HIV or hepatitis, recipients with cancer, and recipients of combined liver-kidney transplants. Patients who also received islet-after-kidney (IAK) transplantation were compared with controls who received kidney transplantation alone according to a 1:2 matching method based on time-dependent propensity scores, ensuring patients comparability at the time of islet transplantation. The primary outcome was patient-graft survival, a composite outcome defined by death, re-transplantation, or return to dialysis. FINDINGS: Between Jan 1, 2000, and Dec 31, 2017, 2391 patients with type 1 diabetes were identified as having received a kidney transplant, 47 patients of whom also received an islet transplantation. 2002 patients were not eligible for islet transplantation and 62 were excluded due to missing data. 327 eligible recipients from 15 centres were included in the study dataset for the target trial emulation. 40 patients who received IAK transplantation were successfully matched to 80 patients who received kidney transplantation alone. 13 (33%) of 40 patients in the IAK transplantation group returned to dialysis or died, compared with 36 (45%) of 80 patients in the kidney transplantation alone group. We found a significant benefit of islet transplantation compared with kidney transplantation alone on patient-graft survival, with a hazard ratio (HR) of 0·44 (95% CI 0·23-0·88; p=0·022), mainly explained by a protective effect on the risk of death (HR 0·41, 0·13-0·91; p=0·042). There was no meaningful association between IAK and death-censored graft survival (0·73, 0·30-1·89; p=0·36). INTERPRETATION: In kidney transplant recipients with type 1 diabetes, IAK transplantation was associated with a significantly better patient-graft survival compared with kidney transplantation alone, mainly due to a protective effect on the risk of death. These results potentially serve as compelling grounds for advocating wider access to islet transplantation in patients with type 1 diabetes undergoing kidney transplant, as reimbursement of islet transplantation is provided in few countries worldwide. FUNDING: Programme Hospitalier de la Recherche Clinique, Fondation pour la Recherche Medicale, and Fonds de Dotation Line Renaud-Loulou Gasté.
引用
- Maanaoui M, Lenain R, Foucher Y, et al. Islet-after-kidney transplantation versus kidney alone in kidney transplant recipients with type 1 diabetes (KAIAK): a population-based target trial emulation in France. Lancet Diabetes Endocrinol. 2024. PMID: 39250921. doi:10.1016/S2213-8587(24)00241-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。